Related Experiment Video
Updated: Feb 16, 2026
07:43
Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons
Published on: January 7, 2019
7.4K
Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability
M J Ibañez-Juliá1, G Berzero2, G Reyes-Botero3
1a Department of Neurology Mazarin , Hôpitaux universitaires Pitié-Salpêtrière Charles Foix. Assistance Publique Hôpitaux de Paris (APHP) , Paris , France.
Acta Oncologica (Stockholm, Sweden)
|December 16, 2017
Summary
Undiagnosed Charcot Marie Tooth (CMT) disease patients are at high risk for severe neurotoxicity from chemotherapy. Early detection of hereditary neuropathy signs is crucial to prevent irreversible nerve damage.
Area of Science:
- Neurology
- Oncology
- Genetics
Background:
- Charcot Marie Tooth (CMT) disease is a common hereditary neuropathy.
- Mild or undiagnosed CMT cases are prevalent.
- Patients with undiagnosed CMT may experience severe neurotoxicity from chemotherapy.
Observation:
- A study identified eight patients with chemotherapy-induced peripheral neuropathy (CIPN) and CMT.
- Seven of these patients had no prior CMT diagnosis.
- Chemotherapy agents included vinca alkaloids, taxanes, and platinum compounds.
Findings:
- Patients developed severe sensory-motor deficits after chemotherapy.
- Neurological deficits persisted despite early drug cessation.
- Some patients experienced severe disability even below standard neurotoxic dose thresholds.
Implications:
- Oncologists should screen for undiagnosed hereditary neuropathies before prescribing neurotoxic chemotherapy.
- A simple checklist may help identify at-risk patients.
- Early detection can prevent severe, irreversible neurotoxicity in susceptible individuals.
More Related Videos
Related Concept Videos
01:26Peripheral Artery Disease IV: Nursing Management
402
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
402
01:21Skeletal Muscle Relaxants: Adverse Effects
907
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
907
01:23Peripheral Artery Disease V: Postoperative Nursing Management
430
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
430
01:27Peripheral Artery Disease III: Interprofessional Care
374
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
374
01:20Myasthenia Gravis: Overview and Treatment
3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
462
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
462